Compound information
- Natural Products
- NACP170767
- Molecular Formula
- C16H15NO3
- Molecular Weight
- 269.10519334 g/mol
- Structure
-
- IUPAC Name
- 4-oxo-3-oxa-13-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(17),2(7),5,8-tetraene-5-carbaldehyde
- InChI
- InChI=1S/C16H15NO3/c18-9-12-8-11-7-10-3-1-5-17-6-2-4-13(14(10)17)15(11)20-16(12)19/h7-9H,1-6H2
- InChI Key
- ZRIWXONEOQIGDI-UHFFFAOYSA-N
- SMILES
- O=CC1=CC=2C=C3C4=C(C2OC1=O)CCCN4CCC3
- CAS
- 142730-52-7
- SuperClass
- Phenylpropanoids and polyketides
- Class
- Coumarins and derivatives
- SubClass
- NaN
- Source
- CNP0410084
Warheads
- Aldehydic carbonyl
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 20 | Ring Count | 4 |
| Heteroatom Count | 4 | Rotatable Bond Count | 1 |
| Hydrogen Bond Acceptor Count | 4 | Hydrogen Bond Donor Count | 0 |
| Topological Polar Surface Area | 50.52 Å2 | LogP | 2.998 |
| LogS | -5.213 | LogD | 2.557 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.043 | Pgp substrate | 0.005 |
| HIA | 0.965 | F20 % | 0.989 |
| F30 % | 0.974 | Caco-2 | -4.639 |
| MDCK | -4.639 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.326 | PPB | 96.891 |
| VD | 1.396 | Fu | 1.143 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.998 | CYP1A2 substrate | 0.781 |
| CYP2A6 substrate | 0.701 | CYP2B6 substrate | 0.661 |
| CYP2C19 inhibitor | 0.955 | CYP2C19 substrate | 0.563 |
| CYP2C8 substrate | 0.591 | CYP2C9 inhibitor | 0.524 |
| CYP2C9 substrate | 0.067 | CYP2D6 inhibitor | 0.055 |
| CYP2D6 substrate | 0.968 | CYP2E1 substrate | 0.177 |
| CYP3A4 inhibitor | 0.163 | CYP3A4 substrate | 0.832 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.334 | CL | 2.452 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.137 | Hepatotoxicity | 0.997 |
| Mutagenicity | 0.817 | Rat Oral Acute Toxicity | 0.131 |
| FDAMDD | 0.665 | Skin Sensitization | 0.954 |
| Carcinogenicity | 0.718 | Eye Corrosion | 0.004 |
| Eye Irritation | 0.035 | Respiratory Toxicity | 0.593 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | 1.776 | IGC50 | 4.881 |
| LC50FM | 3.903 | LC50DM | 3.423 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.68 | NR-AR-LBD | 0.788 |
| NR-AhR | 0.291 | NR-Aromatase | 0.202 |
| NR-ER | 0.644 | NR-ER-LBD | 0.515 |
| NR-PPAR-gamma | 0.883 | SR-ARE | 0.674 |
| SR-ATAD5 | 0.777 | SR-HSE | 0.465 |
| SR-MMP | 0.654 | SR-p53 | 0.882 |
Similar covalent drugs
No similar covalent drugs found for this compound.